January 20, 2016
January 20, 2016 —
Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature — a biomarker — that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery. The biomarker, a protein called CDX2, also helped the researchers identify Stage II colon cancer patients who are most likely to benefit from chemotherapy after surgery.
January 20, 2016
January 20, 2016 —
Researchers at University of California, San Diego School of Medicine and collaborators developed GenomeSpace, a cloud-based, biologist-friendly platform that connects more than 20 bioinformatics software packages and resources for genomic data analysis. The team is now developing and crowdsourcing “recipes” — step-by-step workflows — to better enable non-programming researchers to interpret their genomic data. The work is described in a paper published January 18, 2016 in Nature Methods.
January 14, 2016
January 14, 2016 —
Researchers at University of California, San Diego School of Medicine and Samsara Sciences, Inc., a wholly-owned subsidiary of Organovo Holdings, Inc., have entered into an agreement focused on the development of techniques and methods for the isolation and characterization of liver cells that will help drive new research on liver biology, drug safety and efficacy, and the treatment of liver diseases.
January 7, 2016
January 7, 2016 —
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego have entered into a research collaboration with Janssen Research & Development, LLC (Janssen R&D), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to identify new therapeutic targets for Chagas disease, a parasitic infection that is the leading cause of heart failure in Latin America.
January 7, 2016
January 7, 2016 —
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego have entered into a research collaboration with Janssen Research & Development, LLC (Janssen R&D), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to identify new therapeutic targets for Chagas disease, a parasitic infection that is the leading cause of heart failure in Latin America.
January 4, 2016
January 4, 2016 —
By analyzing peer-reviewed scientific papers that examined the effectiveness of a surgical procedure, researchers at University of California, San Diego School of Medicine provide evidence suggesting that the conclusions of these studies appear to be influenced by the authors’ mentors and medical training.
December 10, 2015
December 10, 2015 —
Researchers at University of California, San Diego School of Medicine and University of Colorado Boulder have discovered that unique and changing microbial communities present during decomposition of human cadavers may provide a reliable “clock” for forensic scientists. The method could be used to estimate time of death in different seasons, as well determine the original location of moved corpses and help locate buried corpses.
October 14, 2015
October 14, 2015 —
The most severe strep infections are often the work of one strain known as M1T1, named for the type of tentacle-like M protein projecting from the bacterium’s surface. Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered a new way M1 contributes to strep virulence — the protein’s ability to hold off antimicrobial peptides. The study is published October 14 by Cell Host & Microbe.
October 13, 2015
October 13, 2015 —
Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments. Tamoxifen treatment in mice also enhances clearance of the antibiotic-resistant bacterial pathogen MRSA and reduces mortality.
October 12, 2015
October 12, 2015 —
Many leukemias are caused by loss of the enzyme Pten. Some anti-leukemia treatments work by inhibiting another enzyme called Shp2. Researchers at University of California, San Diego School of Medicine have now found that mice lacking both of these enzymes can’t produce and sustain enough red blood cells. The study, published October 12 by PNAS, helps explain why anemia is a common side effect of anti-cancer drugs that target enzymes involved in tumor growth.
